Clostridioides difficile (C. difficile) is amongst the most frequently reported micro-organisms in healthcare associated infections in Europe1
It is associated with an increase in length of hospital stay, high morbidity and mortality resulting in both societal and financial burden2
Highly virulent (027-NAP1-BI) strains have caused outbreaks of severe diseasae in Europe and North America and are often resistant to fluoroquinolones3
Although the accurate and rapid diagnosis of C. difficile is essential for effective and timely treatment, this remains an unmet clinical need4
1 Viprey, V. F., Granata, G., & Vendrik, K. (n.d.). European survey on the current surveillance practices, management ... https://www.journalofhospitalinfection.com/article/S0195-6701(22)00365-6/fulltext. 2 Tschudin-Sutter S, et al. Guidance document for prevention of C. difficile infection in acute healthcare settings. Clin Microbiol Infect 2018;24:1051 3 Markovska, R et al. Clostridioides difficile, a new suberbug, Microorganisms 2023, 11, 845. https://doi.org/10.3390/microorganisms11040845 4 Bai Y, Hao Y, Song Z, Chu W, Jin Y, Wang Y. Evaluation of the Cepheid Xpert C. difficile diagnostic assay: an update meta-analysis. Braz J Microbiol. 2021 Dec;52(4):1937-1949.
The Solution
Xpert C. difficile BT provides detection and differentiation of Clostridioidesdifficile & the epidemic 027 strain, with a callout for binary toxin, in 43 minutes from unformed stool specimens
Rapid detection and differentiation of Clostridioides difficile & the epidemic 027 strain optimizes patient management decisions, enables timely and appropriate treatment, and supports infection control and outbreak prevention measures4
5 Peppard W, et al. Implementation of polymerase chain reaction to rule out C. difficile infection is associated with reduced empiric antibiotic duration of therapy. Hosp Pharm. 2014 Jul;49(7):639-43. 6 Casari E, et al. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40).
The Impact
Rapid and accurate detection of toxigenic C. difficile is essential to diagnose CDI to implement optimized therapy and bed management and to help prevent transmission and outbreaks: – 45% reduced empiric therapy5 – 48% reduced isolation days6
Related Products
Xpert SA Nasal Complete
Pre-surgical S. aureus and MRSA in about 65 minutes
Learn more
Xpert Norovirus
Fast and accurate identification of Norovirus GI & GII in as little as one hour* *With early assay termination for positive results. Reporting negative results in 90 minutes.
Learn more
Xpert Carba-R
Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 50 minutes
Learn more
Xpert MRSA NxG
Active MRSA surveillance testing in around 70 minutes
Learn more
Xpert MRSA/SA Blood Culture
Accurate Detection of MRSA and SA in Positive Blood Culture Specimens in About an Hour
Learn more
Xpert MRSA/SA SSTI
Detect MRSA & SA Skin and Soft Tissue Infections In About One Hour
Learn more
Xpert vanA/vanB
Rapid VRE screening for active outbreak prevention and control in around 48 minutes